NCT04254133Enrolling by invitation
Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study
Genetic Information to Inform Treatment and Screening (GIFTS) Study for Prostate Cancer
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1360 (estimated)
- First submitted
- 31 Jan 2020
- Start date
- 30 Nov 2018
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Fred Hutchinson Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT04254133
What you commit to
- Study type: Observational
- Planned participants: 1360
- From 30 Nov 2018 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior bone marrow transplant
- Prior bone marrow transplant
Other illness
- Unable to provide informed consent, e.g., decisional impairment
- Currently under treatment for a hematologic malignancy
- Unable to provide informed consent, e.g., decisional impairment
- Currently under treatment for a hematologic malignancy
Other
- Study team members
- Study team members
Who the study is looking for
- Signed informed consent form providing agreement for germline genetic and molecular testing, use release of health and research information; and
- Male aged 35 to 89 years; and
- Diagnosis of prostate cancer; and
- Resident of Washington state at diagnosis; and
- Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history; and
- Willing and able to provide a saliva sample; and
- United States (U.S.) mailing address.
- Signed informed consent form providing agreement for germline genetic and molecular testing, use release of health and research information; and
- Male aged 35 to 89 years; and
- Diagnosis of prostate cancer; and
- Self-identifies as Black, African American, or African; and
- Receiving care at UWMC or UWHMC; and
- Willing and able to provide a saliva sample; and
- Able to provide either a U.S. mailing address or Email address or Phone number.
- Signed informed consent form providing agreement for germline genetic and molecular testing, use and release of health and research information; and
- Males aged 35 to 89 years; and
- Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history; and
- Willing and able to provide a saliva sample; and
- U.S. mailing address
Age in the registry: 35 years to 89 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.